Genespire Secures €46.6M Series B to Propel First Pediatric Gene Therapy into Clinical Trials

Genespire raises €46.6 million (~$52 million) in a Series B round to advance its first pediatric in-vivo gene therapy into the clinic One of the la...

September 25, 2024 | Wednesday | News
Takeda Receives Japanese Approval for FRUZAQLA® (Fruquintinib) in Metastatic Colorectal Cancer Treatment

— Approval based on results from global Phase III FRESCO-2 trial in patients with previously treated metastatic colorectal cancer — &md...

September 24, 2024 | Tuesday | News
Nicox’s ZERVIATE® Approved for Ocular Itching in China, Set to Launch with Ocumension Therapeutics

Nicox’s partner, Ocumension Therapeutics, has received approval for ZERVIATE® for ocular itching in China ZERVIATE® launch in China wil...

September 18, 2024 | Wednesday | News
Nuance Pharma Expands Bentrio® Nasal Spray Reach Across East and South East Asia

Altamira Therapeutics announces the extension of its exclusive license with Nuance Pharma to cover Singapore, Malaysia, Thailand, Philippines, Indonesia,...

September 17, 2024 | Tuesday | News
PolTREG Secures Chinese Patent for Intrathecal Administration of MS Therapy, Set to Launch Phase 2 Trials

China’s National Intellectual Property Administration has issued notification to grant patent to PolTREG Chinese patent covers intrathecal...

September 16, 2024 | Monday | News
MaxCyte and Kamau Therapeutics Partner to Advance Next-Gen Gene Therapies for Sickle Cell Disease

MaxCyte, Inc.,  a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and comme...

September 16, 2024 | Monday | News
Oneness Biotech and Microbio's Pan-COVID Drug SNS812 Achieves Key Phase 2 Trial Success, Showing Broad-Spectrum Efficacy

Oneness Biotech and Microbio (Shanghai) announced that the pan-COVID New Drug, SNS812, co-developed by both companies achieves statistical significance wit...

September 11, 2024 | Wednesday | News
Vasa Therapeutics' Novel Heart Failure Treatment VS-041 Reaches Key Clinical Advancement with First Dosing in Human Trials

VS-041, a novel and potentially life-saving  treatment for heart failure, developed by Vasa Therapeutics, a San Diego-based biotechnology  comp...

September 11, 2024 | Wednesday | News
Dupixent Phase 3 Study Shows Significant Reductions in Itch and Hives for Patients with Chronic Spontaneous Urticaria (CSU)

Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU Confirming the results of CUPID-A, this second pivot...

September 11, 2024 | Wednesday | News
GC Cell and PT Bifarma Adiluhung Finalize Landmark Technology Transfer Agreement for Immuncell-LC in Indonesia

GC Cell, a leading innovator in cell therapy, has officially announced the execution of a landmark 'Technology Transfer and License Agreement' with PT Bi...

September 11, 2024 | Wednesday | News
Hongene Biotech and ReciBioPharm Forge Strategic Alliance to Enhance Gene Editing Drug Manufacturing

Hongene Biotech Corporation, a global leader in nucleic acid manufacturing, and ReciBioPharm, a leading advanced therapeutics CDMO services provider, hav...

September 09, 2024 | Monday | News
PolTREG’s PTG-007 Treg Therapy Shows Long-Term Remission in Type-1 Diabetes, Up to 12 Years in Some Patients

PTG-007 cell therapy resulted in clinical remission in some patients for up to 12 years A proportion of patients remained insulin-independent for up t...

September 09, 2024 | Monday | News
Nxera Pharma to Receive $35 Million Milestone Payment from Neurocrine Following Successful Phase 2 Schizophrenia Trial

Nxera Pharma Co – formerly known as Sosei Group or Sosei Heptares – announces that it will receive a US$35 million payment from Neurocrine Bi...

September 03, 2024 | Tuesday | News
Guardant Health Japan Receives MHLW Approval for First Blood-Based Diagnostic Test for EGFR Exon 20 Insertion Mutations in NSCLC

Guardant Health Japan Corp. (HQ: Minato-ku, Tokyo/ Representative Director: Mika Takaki), a leading precision oncology company, announced that the M...

September 03, 2024 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close